# A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

> **NCT00451178** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 101 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** vincristine
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00451178
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2012-02
- **Final completion:** 2013-01
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451178, "A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00451178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*